Today we announced our half‑year results. Read the full ASX announcement for details: https://bit.ly/4tzf89M #CSL
CSL's 2026 Half Year Financial Results
We have announced our 2026 Half Year Financial Results for the period ending 31st December 2025.
Like to learn more about Our Impact? Click here to view or download the 2025 Impact Report → | Would you like to read our 2025 Annual Report? Click here to view or download the Annual Report → | CSL's 2025 Full Year Financial Results Click here for Full Information including Webcast Recording →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
11 Feb
What can we do about #rarediseases ? Listen with understanding and acceptance. Be open to learning about the rare conditions that impact millions around the world. #RareDiseaseDay is February 28. https://lnkd.in/gic3d9wJ #PatientVoices #CSL
10 Feb
10 Feb
Today we’ve announced that @[Gordon Naylor] has been appointed interim Chief Executive Officer and Managing Director, following Dr Paul McKenzie’s decision to retire. Read more: http://bit.ly/46DKj9K
9 Feb
Rare Disease Day is February 28th. To shine a light on those battling rare diseases, today we’re highlighting von Willebrand Disease or \(VWD\). According to the CDC, von Willebrand Disease is the most common blood disorder. https://lnkd.in/gZZmTNHx #CSL #RareDiseaseDay #RDD #VWD #VonWillebrandDisease
9 Feb
Our research collaboration with Memo Therapeutics AG , a late-stage biotech company based in Zurich, Switzerland combines CSL’s global leadership in immunoglobulins and expertise in recombinant proteins with Memo Therapeutics’ recombinant polyclonal technology to explore new treatment options for people with rare and serious diseases. This partnership is a prime example of the innovative strength of Zurich's biotech ecosystem, as well as CSL's long-standing and active involvement in the sector.
6 Feb
During National Patient Recognition Week, we’re honoring patients like Arthur who remind us that resilience is often built through support, teamwork and determination. Thank you, Arthur, for sharing your perspective on living with chronic inflammatory demyelinating polyneuropathy. #CSL #NationalPatientRecognitionWeek #PatientRecognition #CIDP #PatientStories
6 Feb
At CSL, collaboration is how innovation moves forward. Our R&D teams work across six global hubs, connecting science, technology and diverse expertise to advance discovery with speed and purpose. Join an environment where global collaboration fuels meaningful impact. Explore opportunities: https://bit.ly/4qocZLg #CSLCareers #RDCareers #LifeSciences #Innovation #CSL #PromisingFutures
5 Feb
During a recent visit to Uzbekistan with the World Federation of Hemophilia / Fédération mondiale de l'hémophilie (WFH) as part of their Humanitarian Aid Program, CSL’s Dr. Sujan Sivasubramaniyam witnessed both progress the healthcare system has made through partnership and ongoing gaps in care for people with inherited bleeding disorders in the central Asian country. Read how collaboration, advocacy, and humanitarian aid are helping change lives: https://lnkd.in/gqn2y9SW #CSL #hemophilia #rarediseases #RareDiseaseDay #patientadvocacy
4 Feb
This National Patient Recognition Week, we’re recognizing the strength of patients like Tim, and the friends, families, and communities who show up with empathy and support. Thank you, Tim, for sharing what it means to feel understood and supported while living with hemophilia and Factor VII deficiency. #CSL #NationalPatientRecognitionWeek #PatientVoices #HemophiliaAwareness
3 Feb
Rare Disease Day is February 28th. To shine a light on those battling rare diseases, today we’re highlighting hemophilia, a rare bleeding disorder that affects the blood's ability to clot. More: https://lnkd.in/gkfd4At3 #CSL #RareDiseaseDay #Hemophilia